SLC22A17 and neoplasm: Unlike LCN2, SLC22A17 was predominantly downregulated in more than 75% of tumor types, showing statistical significance (FC ≥ 1.4 or ≤ −1.4; p ≤ 0.05) for the gene and seven of its isoforms.